Cboe BZX · FIXXHealthcarePharmaceuticals

Leverage Shares 2X Long FIX Daily ETF financials

$13.04+0.13%
Close Sep 28, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$53.7M$0.00-$6.7M$3.2M$34.0M$2.7M$1.7M$5.3M
Gross profit$53.7M$0.00-$6.7M$3.2M$34.0M$2.7M$1.7M$5.3M
Gross margin100.0%—100.0%100.0%100.0%100.0%100.0%100.0%
Operating income$16.9M-$66.1M-$48.3M-$133.3M-$95.9M-$130.3M-$109.9M-$59.9M
Net income$29.8M-$47.7M-$53.7M-$5.0M-$95.8M-$128.7M-$103.9M-$55.6M
Net margin55.5%—808.0%−156.0%−281.9%−4762.9%−6237.5%−1044.3%
Diluted EPS$2.42$-6.58$-153.96$-1.62$-31.14$-50.40$-44.46$-35.10
EBITDA$17.3M-$65.6M-$47.8M-$132.0M-$87.6M-$122.3M-$103.6M-$58.6M
Operating cash flow-$33.5M-$67.7M-$18.7M-$113.7M-$109.8M-$94.3M-$91.4M-$42.6M
Free cash flow-$33.5M-$67.8M-$18.7M-$114.9M-$112.1M-$98.1M-$113.2M-$67.5M
Diluted shares12.3M9.7M0.3M3.2M3.1M2.6M2.3M1.6M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$48.3M$78.0M$25.6M$34.0M$108.4M$217.4M
Short-term investments$0.00$0.00$0.00$141.0M$47.5M$0.00
Total debt$9.7M$12.7M$44.1M$0.00$0.00$0.00
Total assets$61.8M$92.3M$47.1M$228.5M$211.7M$263.7M
Total liabilities$19.8M$86.7M$118.5M$50.5M$42.1M$67.7M
Shareholders' equity$42.0M$5.7M-$182.9M$178.0M$169.7M$196.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology